Company Description
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
The company’s lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 255 |
| CEO | Sekar Kathiresan |
Contact Details
Address: 201 Brookline Avenue, Suite 601 Cambridge, Massachusetts 02215 United States | |
| Phone | 617 603 0070 |
| Website | vervetx.com |
Stock Details
| Ticker Symbol | VERV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001840574 |
| CUSIP Number | 92539P101 |
| ISIN Number | US92539P1012 |
| Employer ID | 82-4800132 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sekar Kathiresan M.D. | Co-Founder, Chief Executive Officer and Director |
| Andrew D. Ashe J.D. | President, Chief Operating Officer and General Counsel |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder |
| Issi Rozen M.B.A. | Co-Founder and Strategic Advisor |
| Dr. Troy Lister Ph.D. | Chief Scientific Officer |
| Joan Nickerson M.B.A. | Chief Administrative Officer |
| Jennifer Robinson | Vice President of Investor Relations and Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 10-Q | Quarterly Report |